How India Exports Pyrazinamide to the World

In the United States, Pyrazinamide is approved for the treatment of tuberculosis. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Pyrazinamide, indicating a competitive generic market. As of March 2026, there are no specific import alerts related to Pyrazinamide. However, general import alerts such as Import Alert 66-66, issued in October 2024, address misbranded active pharmaceutical ingredients (APIs) that do not meet labeling requirements. Additionally, Import Alert 55-05, updated in November 2025, pertains to finished dosage forms and APIs with potential microbiological contamination. These alerts underscore the importance of compliance with FDA regulations for Indian exporters aiming to enter the U.S. market.

In the European Union, Pyrazinamide is subject to marketing authorization by the European Medicines Agency (EMA). Manufacturers must comply with EU Good Manufacturing Practice (GMP) standards to ensure product quality and safety. Similarly, in the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) oversees the approval and regulation of medicinal products, including Pyrazinamide. Compliance with these regulatory bodies is essential for Indian exporters targeting the EU and UK markets.

Pyrazinamide is included in the World Health Organization's (WHO) Model List of Essential Medicines, highlighting its critical role in global health. The WHO Prequalification Programme ensures that medicines meet global standards of quality, safety, and efficacy. Pyrazinamide formulations are subject to pharmacopoeial standards, including those of the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality across different markets.

In India, Pyrazinamide is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for its dispensation. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines, including Pyrazinamide, to ensure affordability. Exporters must obtain a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT) for the export of pharmaceutical products, ensuring compliance with national regulations.

The primary patents for Pyrazinamide have expired, leading to a competitive generic market. This allows multiple manufacturers to produce and export the drug, contributing to its widespread availability and affordability.

In November 2025, the FDA updated Import Alert 55-05 to include additional finished dosage forms and APIs due to concerns over microbiological contamination. This emphasizes the need for stringent quality control measures among exporters.

In October 2024, the FDA issued Import Alert 66-66, focusing on misbranded APIs that fail to meet labeling requirements. This alert serves as a reminder for exporters to ensure compliance with labeling standards to avoid market entry barriers.

In March 2026, the NPPA revised the ceiling price for Pyrazinamide, reflecting changes in production costs and market dynamics. This adjustment impacts pricing strategies for both domestic sales and exports.

In February 2026, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of Pyrazinamide. This underscores the drug's continued importance in global tuberculosis treatment protocols.

In January 2026, the EMA issued new guidelines on GMP compliance for pharmaceutical manufacturers, affecting the production standards for Pyrazinamide intended for the EU market. Adherence to these guidelines is crucial for market access.

These developments highlight the dynamic regulatory environment affecting Pyrazinamide exports from India. Staying informed and compliant with international standards is essential for maintaining market access and ensuring public health.

India's pharmaceutical industry, while robust in manufacturing finished formulations, heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Approximately 60–70% of these essential components are imported from China, underscoring a significant dependency. This reliance poses a risk, as any disruption in the supply chain from China can directly impact the production of medications like Pyrazinamide.

Recent geopolitical tensions have exacerbated these vulnerabilities. In March 2026, the closure of the Strait of Hormuz due to military conflicts led to significant disruptions in global shipping routes, affecting the timely delivery of raw materials and APIs. Such events highlight the fragility of the supply chain and the potential for production delays in the pharmaceutical sector.

The export market for Pyrazinamide is highly concentrated, with the top five exporters accounting for 99.4% of the total exports. LUPIN LIMITED alone holds an 86.6% share, amounting to $833.0 million. This high concentration poses a significant single-source risk; any operational or regulatory issues faced by these key suppliers could disrupt the entire supply chain.

To mitigate such risks, the Indian government has introduced the Production Linked Incentive (PLI) scheme, aiming to boost domestic manufacturing of APIs and reduce dependency on imports. However, the effectiveness of this initiative in diversifying the supplier base for Pyrazinamide remains to be fully realized.

The closure of the Strait of Hormuz in March 2026, following military escalations, led to a near halt in shipping traffic through this critical passage. This disruption affected approximately 20% of the world's daily oil supply and significant volumes of liquefied natural gas, causing a ripple effect across global supply chains. Shipping companies were forced to reroute vessels around the Cape of Good Hope, adding 10–14 days to transit times and increasing costs by up to $1 million per trip. Such delays and increased expenses have direct implications for the timely export of pharmaceuticals like Pyrazinamide.

Additionally, the ongoing U.S.-China trade tensions have introduced further uncertainties. While these tensions have primarily impacted sectors like technology and manufacturing, the interconnected nature of global trade means that the pharmaceutical industry is not immune to potential disruptions stemming from geopolitical conflicts.

• Diversify Supplier Base: Encourage the development of alternative suppliers for APIs and KSMs to reduce dependency on a single country or company.

• Enhance Domestic Production: Leverage government initiatives like the PLI scheme to bolster domestic manufacturing capabilities for critical pharmaceutical components.

• Strengthen Supply Chain Resilience: Develop contingency plans, including alternative shipping routes and strategic stockpiling, to mitigate the impact of geopolitical disruptions.

• Monitor Geopolitical Developments: Establish a dedicated team to track international events that could affect supply chains and proactively adjust strategies accordingly.

• Foster International Collaboration: Engage with global partners to create a more robust and diversified supply network, reducing the impact of regional disruptions.

RISK_LEVEL: HIGH